CA2570606A1 - Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders - Google Patents
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders Download PDFInfo
- Publication number
- CA2570606A1 CA2570606A1 CA002570606A CA2570606A CA2570606A1 CA 2570606 A1 CA2570606 A1 CA 2570606A1 CA 002570606 A CA002570606 A CA 002570606A CA 2570606 A CA2570606 A CA 2570606A CA 2570606 A1 CA2570606 A1 CA 2570606A1
- Authority
- CA
- Canada
- Prior art keywords
- benzo
- dihydro
- dioxinyl
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
Abstract
The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical composlons containing them and their use in the treatment of epilepsy and related disorders.
Claims (15)
1. A compound of formula (II) IMG>
wherein R1 and R2 are each independently selected from the group consisting of hydrogen and lower alkyl;
R4 is selected from the group consisting of hydrogen and lower alkyl;
a is an integer from 1 to 2;
is selected from the group consisting of wherein b is an integer from 0 to 4; and wherein c is an integer from 0 to 2;
each R5 is independently selected from the group consisting of halogen, lower alkyl and nitro;
provided that when then a is 1;
or a pharmaceutically acceptable salt thereof.
wherein R1 and R2 are each independently selected from the group consisting of hydrogen and lower alkyl;
R4 is selected from the group consisting of hydrogen and lower alkyl;
a is an integer from 1 to 2;
is selected from the group consisting of wherein b is an integer from 0 to 4; and wherein c is an integer from 0 to 2;
each R5 is independently selected from the group consisting of halogen, lower alkyl and nitro;
provided that when then a is 1;
or a pharmaceutically acceptable salt thereof.
2. A compound as in Claim 1 wherein R1 and R2 are each independently selected from the group consisting of hydrogen and lower alkyl;
R4 is selected from the group consisting of hydrogen and lower alkyl;
a is an integer from 1 to 2;
is selected from the group consisting of wherein b is an integer from 0 to 2; and wherein c is an integer from 0 to 1;
each R5 is independently selected from the group consisting of halogen, lower alkyl and nitro;
provided that when then a is 1;
or a pharmaceutically acceptable salt thereof.
R4 is selected from the group consisting of hydrogen and lower alkyl;
a is an integer from 1 to 2;
is selected from the group consisting of wherein b is an integer from 0 to 2; and wherein c is an integer from 0 to 1;
each R5 is independently selected from the group consisting of halogen, lower alkyl and nitro;
provided that when then a is 1;
or a pharmaceutically acceptable salt thereof.
3. A compound as in Claim 2 wherein R1 and R2 are each independently selected from the group consisting of hydrogen and lower alkyl;
R4 is selected from the group consisting of hydrogen and lower alkyl;
a is an integer from 1 to 2;
is selected from the group consisting of wherein b is an integer from 0 to 2; and wherein c is 0;
each R5 is independently selected from the group consisting of halogen, lower alkyl and nitro;
provided that when then a is 1;
or a pharmaceutically acceptable salt thereof.
R4 is selected from the group consisting of hydrogen and lower alkyl;
a is an integer from 1 to 2;
is selected from the group consisting of wherein b is an integer from 0 to 2; and wherein c is 0;
each R5 is independently selected from the group consisting of halogen, lower alkyl and nitro;
provided that when then a is 1;
or a pharmaceutically acceptable salt thereof.
4. A compound as in Claim 3 wherein R' and R2 are each independently selected from the group consisting of hydrogen and lower alkyl;
R4 is selected from the group consisting of hydrogen and methyl;
a is an integer from 1 to 2;
<1MG>
is selected from the group consisting of 2-(2,3-dihydro-benzo[1,4]dioxinyl), 2-(benzo[1,3]dioxolyl), 3-(3,4-dihydro-2H-benzo[1,4]dioxepinyl), 2-(2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-fluoro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(chromanyl), 2-(5-fluoro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(7-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-chloro-benzo[1,3]dioxolyl), 2-(7-nitro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(7-methyl-2,3-dihydro-benzo[1,4]dioxinyl), 2-(5-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-bromo-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6,7-dichloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(3-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(2,3-dihydro-naphtho[2,3-b][1,4]dioxinyl) and 2-(4-methyl-benzo[1,3]dioxolyl);
provided that when is 3-(3,4-dihydro-2H-benzo[1,4]dioxepinyl), then a is 1;
or a pharmaceutically acceptable salt thereof.
R4 is selected from the group consisting of hydrogen and methyl;
a is an integer from 1 to 2;
<1MG>
is selected from the group consisting of 2-(2,3-dihydro-benzo[1,4]dioxinyl), 2-(benzo[1,3]dioxolyl), 3-(3,4-dihydro-2H-benzo[1,4]dioxepinyl), 2-(2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-fluoro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(chromanyl), 2-(5-fluoro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(7-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-chloro-benzo[1,3]dioxolyl), 2-(7-nitro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(7-methyl-2,3-dihydro-benzo[1,4]dioxinyl), 2-(5-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-bromo-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6,7-dichloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(3-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(2,3-dihydro-naphtho[2,3-b][1,4]dioxinyl) and 2-(4-methyl-benzo[1,3]dioxolyl);
provided that when is 3-(3,4-dihydro-2H-benzo[1,4]dioxepinyl), then a is 1;
or a pharmaceutically acceptable salt thereof.
5. A compound as in Claim 4 wherein R1 and R2 are each independently selected from the group consisting of hydrogen and methyl;
R4 is selected from the group consisting of hydrogen and methyl;
a is an integer from 1 to 2;
is selected from the group consisting of 2-(benzo[1,3]dioxolyl), 2-(2,3-dihydro-benzo[1,4]dioxinyl), 2-(2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(7-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(7-methyl-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-bromo-2,3-dihydro-benzo[1,4]dioxinyl) and 2-(6,7-dichloro-2,3-dihydro-benzo[1,4]dioxinyl);
or a pharmaceutically acceptable salt thereof.
R4 is selected from the group consisting of hydrogen and methyl;
a is an integer from 1 to 2;
is selected from the group consisting of 2-(benzo[1,3]dioxolyl), 2-(2,3-dihydro-benzo[1,4]dioxinyl), 2-(2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(7-chloro-2,3-dihydro-benzo[1,4]dioxinyl), 2-(7-methyl-2,3-dihydro-benzo[1,4]dioxinyl), 2-(6-bromo-2,3-dihydro-benzo[1,4]dioxinyl) and 2-(6,7-dichloro-2,3-dihydro-benzo[1,4]dioxinyl);
or a pharmaceutically acceptable salt thereof.
6. A compound selected from the group consisting of N-[(6-chloro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-sulfamide and pharmaceutically acceptable salts thereof.
7. A compound selected from the group consisting of and pharmaceutically acceptable salts thereof.
8. A compound of the formula (III) or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.
10. A pharmaceutical composition made by mixing a compound of Claim I
and a pharmaceutically acceptable carrier.
and a pharmaceutically acceptable carrier.
11. A process for making a pharmaceutical composition comprising mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
12. A method of treating epilepsy or a related disorder, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.
13. A method of treating epilepsy, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.
14. A method as in Claim 12, wherein the disorder is selected from essential tremor or restless limb syndrome.
15. The use of compound as in Claim 1 in the preparation of a medicament for treating epilepsy or a related disorder, in a subject in need thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58017804P | 2004-06-16 | 2004-06-16 | |
| US60/580,178 | 2004-06-16 | ||
| PCT/US2005/021513 WO2006007435A1 (en) | 2004-06-16 | 2005-06-16 | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2570606A1 true CA2570606A1 (en) | 2006-01-19 |
| CA2570606C CA2570606C (en) | 2013-04-30 |
Family
ID=34972935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2570606A Expired - Fee Related CA2570606C (en) | 2004-06-16 | 2005-06-16 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8084490B2 (en) |
| EP (1) | EP1768970B1 (en) |
| JP (2) | JP4884378B2 (en) |
| CN (1) | CN101006072B (en) |
| AR (2) | AR049398A1 (en) |
| AU (1) | AU2005262496B2 (en) |
| BR (1) | BRPI0512242A (en) |
| CA (1) | CA2570606C (en) |
| CR (1) | CR8858A (en) |
| EA (1) | EA013685B1 (en) |
| EC (1) | ECSP067093A (en) |
| ES (1) | ES2573844T3 (en) |
| IL (1) | IL180108A (en) |
| MX (1) | MXPA06014934A (en) |
| MY (1) | MY147767A (en) |
| NI (1) | NI200600306A (en) |
| NO (1) | NO20070081L (en) |
| NZ (1) | NZ552056A (en) |
| TW (1) | TWI361691B (en) |
| UA (1) | UA91680C2 (en) |
| WO (1) | WO2006007435A1 (en) |
| ZA (1) | ZA200700430B (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| AR049646A1 (en) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS |
| US20060047001A1 (en) * | 2004-08-24 | 2006-03-02 | Parker Michael H | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
| WO2006127184A1 (en) | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| US8716231B2 (en) * | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US20070155824A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| TWI398248B (en) * | 2005-12-19 | 2013-06-11 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for disease modification/epileptogenesis |
| AR058389A1 (en) * | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
| US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
| AU2007253814A1 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
| EP2238122A1 (en) * | 2008-01-07 | 2010-10-13 | Janssen Pharmaceutica, N.V. | Preparation of sulfamide derivatives |
| EA201071120A1 (en) * | 2008-03-26 | 2011-06-30 | Янссен Фармацевтика Н.В. | METHOD OF OBTAINING HETEROARILBENZE DERIVATIVES OF SULFAMATES AND CRYSTALLINE FORM N - ((2S) -6-CHLOR-2,3-DIGYDRO-L, 4-BENZODIOXIN-2-IL) METHYL SULFAMIDE |
| JP2011517448A (en) * | 2008-03-26 | 2011-06-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Process for the preparation of benzo-fused dioxin derivatives |
| US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
| US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
| AU2009242092A1 (en) * | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| CN102015674B (en) * | 2008-04-29 | 2014-10-29 | Nsab神经研究瑞典公司分公司 | Modulators of dopamine neurotransmission |
| JP2011519839A (en) * | 2008-04-29 | 2011-07-14 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | Modulator of dopamine neurotransmission |
| PE20110060A1 (en) | 2008-06-23 | 2011-01-31 | Janssen Pharmaceutica Nv | CRYSTALLINE FORM OF (2S) - (-) - N- (6-CHLORO-2,3-DIHYDRO-BENZO [1,4] DIOXIN-2-ILMETHYL) -SULFAMIDE |
| US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| CN102574782B (en) * | 2009-10-21 | 2014-10-08 | 拜耳知识产权有限责任公司 | Substituted halophenoxybenzamide derivatives |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| AU2012314317A1 (en) | 2011-09-29 | 2014-04-03 | Janssen Pharmaceutica Nv | Improved process for the preparation of sulfamide derivatives |
| KR20140082736A (en) * | 2011-09-29 | 2014-07-02 | 얀센 파마슈티카 엔.브이. | Process for the preparation of sulfamide derivatives |
| WO2014140220A1 (en) | 2013-03-13 | 2014-09-18 | Janssen Pharmaceutica, N.V. | Process for the preparation of (2,3-dihydro-benzo[b][1,4]dioxin-2-yl) methanol derivatives |
| EP3079687B1 (en) | 2013-12-12 | 2018-02-28 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating pain |
| US9834535B2 (en) | 2013-12-12 | 2017-12-05 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating pain |
| KR101792999B1 (en) | 2013-12-12 | 2017-11-02 | (주)바이오팜솔루션즈 | Sulfamate derivate compound for use in preventing or treating epilepsy |
| USD827368S1 (en) | 2015-09-17 | 2018-09-04 | Traeger Pellet Grills, Llc | Grill handle towel bar assembly |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US480663A (en) * | 1892-08-09 | William h | ||
| US2527861A (en) * | 1948-05-07 | 1950-10-31 | Monsanto Chemicals | Mono alkyl sulfamides |
| BE636655A (en) * | 1962-09-14 | |||
| DE1211166B (en) | 1962-11-20 | 1966-02-24 | Ciba Geigy | Process for the production of new sulfamides |
| US3318952A (en) * | 1964-01-22 | 1967-05-09 | Sandoz Ag | Dibenzylsulfamides |
| US3320314A (en) | 1964-01-22 | 1967-05-16 | Sandoz Ag | Chlorobenzyl sulfamides |
| US3383414A (en) * | 1964-08-26 | 1968-05-14 | Sandoz Ag | Benzocycloalkyl sulfamides |
| DE1542785A1 (en) | 1965-07-24 | 1970-05-06 | Bayer Ag | Insect and mite repellants |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3621096A (en) * | 1969-04-03 | 1971-11-16 | Univ North Carolina | Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone |
| DE2022370A1 (en) | 1970-05-08 | 1971-12-02 | Bayer Ag | N-fluorodichloromethylthio-sulfamic acid derivatives, process for their preparation and their microbicidal and fungicidal use |
| US5212326A (en) * | 1979-08-20 | 1993-05-18 | Abbott Laboratories | Sodium hydrogen divalproate oligomer |
| FR2479825A1 (en) * | 1980-04-04 | 1981-10-09 | Fabre Sa Pierre | BENZODIOXAN 1,4 METHOXY-2 PROPANOLAMINES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5238945A (en) * | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
| GB8908085D0 (en) * | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
| US5273993A (en) * | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
| US5194446A (en) * | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
| US5192785A (en) * | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
| US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5189179A (en) | 1990-08-29 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Serotonin 5ht1a agonists |
| AU641052B2 (en) | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
| GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
| US5120758A (en) | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
| GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
| IL103172A (en) * | 1991-09-19 | 1997-01-10 | Mcneilab Inc | Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol |
| SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
| US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5258402A (en) * | 1992-06-11 | 1993-11-02 | Mcneil-Ppc, Inc. | Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates |
| US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| TW274550B (en) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| AU695336B2 (en) | 1993-12-23 | 1998-08-13 | Ortho Pharmaceutical Corporation | Anticonvulsant pseudofructopyranose sulfamates |
| GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
| CA2216648A1 (en) * | 1995-02-15 | 1996-08-22 | Bearsden Bio, Inc. | Alkylcarboxy amino acids-modulators of the kainate receptor |
| JP3235448B2 (en) * | 1995-03-24 | 2001-12-04 | ダイソー株式会社 | Method for producing 1,4-benzodioxane derivative |
| US5998380A (en) * | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
| AU7655796A (en) | 1995-11-30 | 1997-06-19 | C & C Research Laboratories | Sulfamide derivatives |
| WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| AU2587297A (en) | 1996-03-25 | 1997-10-17 | Eli Lilly And Company | Method for treating pain |
| US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
| US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
| UA53655C2 (en) | 1996-06-28 | 2003-02-17 | Орто-Макнейл Фармасьютікел, Інк. | Method for treating obesity |
| WO1998000124A1 (en) | 1996-06-28 | 1998-01-08 | Ortho Pharmaceutical Corporation | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration |
| US5841399A (en) | 1996-06-28 | 1998-11-24 | Alliedsignal Inc. | Fault detection and exclusion used in a global positioning system GPS receiver |
| ES2188971T3 (en) | 1996-08-14 | 2003-07-01 | Searle & Co | CRYSTAL FORM OF THE 4- (5-METHYL-3-PHENYLISOXAZOL-4-IL) BENZENSULFONAMIDE. |
| JP2001500121A (en) * | 1996-08-23 | 2001-01-09 | アルゴス ファーマシューティカル コーポレーション | Anticonvulsants comprising a composition for treating neuropathic pain |
| WO1998015270A1 (en) | 1996-10-08 | 1998-04-16 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
| US20020015713A1 (en) * | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
| KR100499106B1 (en) * | 1996-12-10 | 2005-07-01 | 브리스톨-마이어즈 스퀴브 컴페니 | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents |
| US5935933A (en) * | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
| US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
| DE69827149T2 (en) * | 1997-08-15 | 2006-03-09 | Fairbanks, Carolyn Ann, Rochester | AGMATIN FOR THE TREATMENT OF NEUROPATHIC PAIN |
| DE19742508A1 (en) * | 1997-09-26 | 1999-04-01 | Hoechst Marion Roussel De Gmbh | Sulfonamide-substituted chromanes, processes for their preparation, their use as medicaments or diagnostic agents and pharmaceutical preparations containing them |
| TR200001927T2 (en) * | 1997-12-19 | 2001-06-21 | Bayer Corporation | Carboxyl substituted chromone derivatives useful as beta 3 adrenoreceptor agonists. |
| GB9803536D0 (en) | 1998-02-19 | 1998-04-15 | Black James Foundation | Histamine H,receptor ligands |
| UA65607C2 (en) | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Pharmaceutical composition (variants) and process for its preparation |
| JP2002516864A (en) | 1998-05-29 | 2002-06-11 | イーライ・リリー・アンド・カンパニー | Combination therapy for treatment of bipolar disease |
| EP1100504A2 (en) | 1998-07-02 | 2001-05-23 | Eisai Co., Ltd. | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| US6541520B1 (en) | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| US6319903B1 (en) | 1999-01-19 | 2001-11-20 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cluster headaches |
| AR022321A1 (en) | 1999-01-21 | 2002-09-04 | Ortho Mcneil Pharm Inc | USEFUL ANTI-CONVULSIVE DERIVATIVES FOR THE TREATMENT OF TRANSFORMED MIGRANE |
| HUP0200469A3 (en) | 1999-02-24 | 2003-03-28 | Univ Cincinnati Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
| AU3898700A (en) | 1999-03-15 | 2000-10-04 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| CA2369093C (en) * | 1999-04-08 | 2005-10-18 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering lipids |
| WO2000061140A1 (en) | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
| CA2369095C (en) * | 1999-04-08 | 2006-07-25 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
| NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
| CA2372806A1 (en) | 1999-05-04 | 2000-11-09 | Keith R. Edwards | Intravenous valproate for acute treatment of migraine headache |
| EP2308481B1 (en) | 1999-06-14 | 2015-05-06 | Vivus, Inc. | Combination therapy for the treatment of hypertension associated with obesity |
| WO2001013904A2 (en) * | 1999-08-20 | 2001-03-01 | Ortho-Mcneil Pharmaceutical, Inc. | Composition comprising a tramadol material and an anticonvulsant drug |
| FR2803848B1 (en) | 2000-01-19 | 2002-02-15 | Adir | NOVEL BENZENESULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US6322503B1 (en) * | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| MY126897A (en) * | 2000-07-07 | 2006-10-31 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x |
| DE10035227A1 (en) | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity |
| US6627653B2 (en) * | 2000-08-02 | 2003-09-30 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
| US7256184B2 (en) * | 2000-10-16 | 2007-08-14 | Rodriguez Victorio C | Treatment of aging disorders in humans |
| AU2002240235B2 (en) * | 2001-01-30 | 2006-07-06 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| JP2004536071A (en) | 2001-05-25 | 2004-12-02 | クイーンズ ユニバーシティ アット キングストン | Heterocyclic beta amino acids and their use as antiepileptic agents |
| US20030100594A1 (en) | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| US6559293B1 (en) * | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| RU2246727C2 (en) | 2003-02-12 | 2005-02-20 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) | Method for predicting pre-clinical stage of epilepsy |
| RU2226357C1 (en) | 2003-02-12 | 2004-04-10 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева | Method for diagnosing the cases of epilepsy at preclinical development state |
| WO2004092216A1 (en) | 2003-04-15 | 2004-10-28 | Trangene S.A. | Carcinoembryonic antigen (cea) lacking a signal peptide, nucleic acid encoding it and fusion of cea with a t cell epitope and their use for the treatment and/or prophylaxis of cancer |
| EP1615629B1 (en) | 2003-04-16 | 2009-03-18 | Smithkline Beecham Corporation | Peptide deformylase inhibitors |
| JPWO2004093912A1 (en) | 2003-04-23 | 2006-07-13 | 協和醗酵工業株式会社 | Preventive and / or therapeutic agent for neutrophilic inflammatory disease |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| US6949518B1 (en) * | 2003-06-25 | 2005-09-27 | Pao-Hsien Chu | Methods for treating macular degeneration with topiramate |
| CN1845914A (en) | 2003-09-02 | 2006-10-11 | 默克公司 | Ophthalmic compositions for treating ocular hypertension |
| CN1897950A (en) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | Fused-aryl and heteroaryl derivatives and methods of their use |
| AR049646A1 (en) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS |
| MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| JP5026963B2 (en) | 2004-06-22 | 2012-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Heterocyclic derivatives for adjusting calcium channels |
| PL1781639T3 (en) | 2004-07-28 | 2012-07-31 | Janssen Pharmaceutica Nv | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| US20060047001A1 (en) | 2004-08-24 | 2006-03-02 | Parker Michael H | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
| US20060276528A1 (en) * | 2004-08-24 | 2006-12-07 | Abdel-Magid Ahmed F | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
| WO2006127184A1 (en) * | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US20070155824A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US20070155823A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| AR058389A1 (en) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
| US20070155827A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| US20070191452A1 (en) | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain |
| US20070191474A1 (en) | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
| TW200738669A (en) | 2006-02-22 | 2007-10-16 | Janssen Pharmaceutica Nv | Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide |
| AU2007253814A1 (en) * | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
| US20070293476A1 (en) * | 2006-05-19 | 2007-12-20 | Smith-Swintosky Virginia L | Co-therapy for the treatment of epilepsy and related disorders |
| EP2238122A1 (en) | 2008-01-07 | 2010-10-13 | Janssen Pharmaceutica, N.V. | Preparation of sulfamide derivatives |
| JP2011517448A (en) | 2008-03-26 | 2011-06-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Process for the preparation of benzo-fused dioxin derivatives |
| EA201071120A1 (en) | 2008-03-26 | 2011-06-30 | Янссен Фармацевтика Н.В. | METHOD OF OBTAINING HETEROARILBENZE DERIVATIVES OF SULFAMATES AND CRYSTALLINE FORM N - ((2S) -6-CHLOR-2,3-DIGYDRO-L, 4-BENZODIOXIN-2-IL) METHYL SULFAMIDE |
| US20090247618A1 (en) * | 2008-03-26 | 2009-10-01 | Ballentine Scott A | Process for preparation of benzo-fused heteroaryl derivatives |
| US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
| PE20110060A1 (en) * | 2008-06-23 | 2011-01-31 | Janssen Pharmaceutica Nv | CRYSTALLINE FORM OF (2S) - (-) - N- (6-CHLORO-2,3-DIHYDRO-BENZO [1,4] DIOXIN-2-ILMETHYL) -SULFAMIDE |
-
2005
- 2005-06-14 MY MYPI20052699A patent/MY147767A/en unknown
- 2005-06-15 AR ARP050102445A patent/AR049398A1/en active IP Right Grant
- 2005-06-15 TW TW094119737A patent/TWI361691B/en not_active IP Right Cessation
- 2005-06-16 BR BRPI0512242-2A patent/BRPI0512242A/en active Search and Examination
- 2005-06-16 ES ES05763399.2T patent/ES2573844T3/en active Active
- 2005-06-16 WO PCT/US2005/021513 patent/WO2006007435A1/en active Application Filing
- 2005-06-16 EP EP05763399.2A patent/EP1768970B1/en active Active
- 2005-06-16 EA EA200700035A patent/EA013685B1/en not_active IP Right Cessation
- 2005-06-16 CA CA2570606A patent/CA2570606C/en not_active Expired - Fee Related
- 2005-06-16 NZ NZ552056A patent/NZ552056A/en not_active IP Right Cessation
- 2005-06-16 MX MXPA06014934A patent/MXPA06014934A/en active IP Right Grant
- 2005-06-16 US US11/154,443 patent/US8084490B2/en not_active Expired - Fee Related
- 2005-06-16 JP JP2007516788A patent/JP4884378B2/en not_active Expired - Fee Related
- 2005-06-16 CN CN2005800274918A patent/CN101006072B/en not_active Expired - Fee Related
- 2005-06-16 UA UAA200613517A patent/UA91680C2/en unknown
- 2005-06-16 AU AU2005262496A patent/AU2005262496B2/en not_active Ceased
-
2006
- 2006-12-14 IL IL180108A patent/IL180108A/en not_active IP Right Cessation
- 2006-12-15 NI NI200600306A patent/NI200600306A/en unknown
- 2006-12-18 EC EC2006007093A patent/ECSP067093A/en unknown
-
2007
- 2007-01-05 NO NO20070081A patent/NO20070081L/en not_active Application Discontinuation
- 2007-01-15 ZA ZA200700430A patent/ZA200700430B/en unknown
- 2007-01-15 CR CR8858A patent/CR8858A/en not_active Application Discontinuation
-
2011
- 2011-07-04 JP JP2011148530A patent/JP5416740B2/en not_active Expired - Fee Related
-
2013
- 2013-06-10 AR ARP130102038 patent/AR091400A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR049398A1 (en) | 2006-07-26 |
| WO2006007435A1 (en) | 2006-01-19 |
| IL180108A0 (en) | 2007-05-15 |
| US8084490B2 (en) | 2011-12-27 |
| TWI361691B (en) | 2012-04-11 |
| AU2005262496A1 (en) | 2006-01-19 |
| MXPA06014934A (en) | 2007-08-21 |
| NZ552056A (en) | 2010-08-27 |
| IL180108A (en) | 2015-10-29 |
| ECSP067093A (en) | 2007-01-26 |
| ES2573844T3 (en) | 2016-06-10 |
| NO20070081L (en) | 2007-02-26 |
| ZA200700430B (en) | 2008-07-30 |
| JP2011246472A (en) | 2011-12-08 |
| AR091400A2 (en) | 2015-02-04 |
| EP1768970B1 (en) | 2016-03-09 |
| EP1768970A1 (en) | 2007-04-04 |
| CA2570606C (en) | 2013-04-30 |
| EA013685B1 (en) | 2010-06-30 |
| NI200600306A (en) | 2007-11-27 |
| US20060041008A1 (en) | 2006-02-23 |
| JP4884378B2 (en) | 2012-02-29 |
| JP2008503487A (en) | 2008-02-07 |
| JP5416740B2 (en) | 2014-02-12 |
| CN101006072A (en) | 2007-07-25 |
| MY147767A (en) | 2013-01-31 |
| CN101006072B (en) | 2011-10-19 |
| UA91680C2 (en) | 2010-08-25 |
| CR8858A (en) | 2009-01-14 |
| BRPI0512242A (en) | 2008-02-19 |
| EA200700035A1 (en) | 2007-06-29 |
| AU2005262496B2 (en) | 2011-10-20 |
| TW200611702A (en) | 2006-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2570606A1 (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| JP2009520035A5 (en) | ||
| JP2009520036A5 (en) | ||
| JP2009520030A5 (en) | ||
| HRP20110008T1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels | |
| AU2012203164B2 (en) | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders | |
| JP2009520031A5 (en) | ||
| JP2009520032A5 (en) | ||
| HRP20110384T1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
| AU2006331637B2 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity | |
| HRP20100007T1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | |
| JP2009520033A5 (en) | ||
| JP2009520034A5 (en) | ||
| PE20080716A1 (en) | COTHERAPY CONSTITUTED BY A BENZOFUSIONED HETEROCICLOSULFAMIDE DERIVATIVE AND ONE OR SEVERAL ANTI-CONFUSION AND / OR ANTILEPTIC AGENTS | |
| AU2008353489B2 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety | |
| RU2005126459A (en) | DIAZEPANE DERIVATIVES USED AS LFA INHIBITORS | |
| KR101198831B1 (en) | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders | |
| TWI387455B (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180618 |